Tucker H, et al. - Patients with confirmed Acinetobacter spp. isolates who were treated with tigecycline were examined for clinical outcomes in randomized clinical trials. Findings demonstrated that tigecycline could be considered for Acinetobacter infections alone or in combination with other anti-infective agents with appropriate monitoring when other therapies are not suitable.

Methods

• Using descriptive statistics, researchers analyzed data from 14 multinational, randomized (open-label or double-blind), and active-controlled (except one) Phase III and IV studies.

Results

• Researchers recognized 174 microbiologically evaluable patients with Acinetobacter spp. infections (including MDR infections).
• Out of them, 95 received tigecycline to treat community-acquired pneumonia (CAP), diabetic foot infections (DFIs), hospital-acquired pneumonia (HAP), complicated intra-abdominal infections (cIAIs), infections with resistant pathogens (RPs), or complicated skin and skin-structure infections.
• For most indications, the rate of cure of tigecycline was 70%–80%; this was highest (88.2%) in cIAIs.
• Compared to tigecycline, the rate of cure of the comparators was generally higher, but within each indication the 95% CIs for clinical cure for each treatment group overlapped.
• The minimum inhibitory concentration of tigecycline for most Acinetobacter isolates was 0.12–2 μg/mL, with seven at 4 μg/mL and one at 8 μg/mL.
• For all Acinetobacter, the cure rate by tigecycline was 50% (95% CI 12.5%–87.5% in CAP) to 88.2% (95% CI 66.2%–97.1% in cIAIs), and for MDR Acinetobacter, the corresponding values were 72.7% (95% CI 54.5%–93.2% in HAP) to 100% (95% CI 25%–100.0% in cIAIs) .
• The analogous values were 83.8% (95% CI 62.8%–95.9% in HAP) to 100% (95% CI 75%–100% in cIAIs and 25%–100.0% in RPs) and 88% (95% CI 66%–97% in HAP) to 100% (95% CI 25%–100% in cIAIs and 75%–100% in DFIs), respectively, for comparators.